Government of Brazil signs grant agreement for US$ 20 million in support to IFFIm
Government of Brazil signs grant agreement for US$ 20 million in support to IFFIm
11 October 2018
During this year's United Nations General Assembly in New York, Brazil’s Minister of Health, Gilberto Occhi, Dr. Seth Berkley, CEO of Gavi, and Christopher Egerton-Warburton, a member of the IFFIm Board of Directors, met to discuss the Brazil's US$ 20 million commitment to IFFIm. Credit: Gavi/2018/Andrew Seng.
Becomes second BRICS donor to support accelerated funding for Gavi immunisation programmes in the world's poorest countries.
Becomes second BRICS donor to support accelerated funding for Gavi immunisation programmes in the world's poorest countries
London – 11 October 2018 – The Government of Brazil formally approved today a grant of US$ 20 million to the International Finance Facility for Immunisation, or IFFIm, which will accelerate the availability of funding for immunisation programmes supported by Gavi, the Vaccine Alliance. Brazil’s commitment of $1 million per year for 20 years makes it the 10th donor to IFFIm overall and the second BRICS donor after South Africa.
The approval today follows a meeting at the time of the annual United Nations General Assembly in New York City last month, when Brazil’s Minister of Health, Gilberto Occhi, Dr. Seth Berkley, CEO of Gavi, and Christopher Egerton-Warburton, a member of the IFFIm Board of Directors, met to discuss the country’s commitment.
“Brazil’s grant is important not only because it will provide additional funding for immunisation in the poorest countries,” said Cyrus Ardalan, Chair of IFFIm’s Board of Directors. “It also sends a powerful message that Brazil can play a leading role in efforts to solve some of the biggest public health challenges around the globe.”
“The partnership with Gavi is strategic due to its decentralised pursuit of technology development and inputs manufacturing, as well as for Gavi’s vision to guarantee expanded access to vaccines,” said Minister Occhi. “This agenda contributes to the sustainability of health systems around the world. Brazil also seeks to contribute by strengthening its vaccines industrial complex to expand global capacity in dealing with health emergencies.”
Brazil has a longstanding commitment to ensuring access to medicines and vaccines at the domestic, regional and international levels. The Ministry of Health has prioritised the promotion of Brazil’s science and technology complex and its engagement in international health issues. Brazil’s state-owned vaccine manufacturer, Bio-Manguinhos, is one of the only four global yellow fever vaccine suppliers and has provided the vaccine to Gavi.
Brazil is IFFIm’s first donor from Latin America, and it joins nine other donors: Australia, France, Italy, The Netherlands, Norway, Spain, South Africa, Sweden and the United Kingdom. Brazil’s grant brings combined donor grants to IFFIm to US$ 6.55 billion.
“We’re immensely pleased that the Brazilian Government and people have joined nine other countries to help IFFIm continue its engagement of private sector investors in support of critical immunisation programmes,” said Dr. Berkley. “Brazil’s announcement strengthens Gavi’s capacity to marshal all available resources. That means many more children around the world will get the vaccines they need to survive and thrive.”
IFFIm, one of the world’s leading socially responsible investment mechanisms, is a pioneering global development finance tool launched by Gavi. Based on grants from donor governments like Brazil, IFFIm sells bonds on the capital markets and makes funds immediately available for immunisation programmes in developing countries. Since 2006, IFFIm has disbursed more than US$ 2.5 billion that Gavi has used to introduce and maintain routine vaccination programmes in the world’s 73 poorest countries. IFFIm’s innovative frontloading mechanism has made it possible for more than 80 million children to be vaccinated ahead of receiving the donors’ grants.
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.
Reflections on IFFIm: an interview with Rachel Turner
14 November 2024